These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 16959246)

  • 21. Wild-type JAK2 secondary acute erythroleukemia developing after JAK2-V617F-mutated primary myelofibrosis.
    Kreft A; Springer E; Lipka DB; Kirkpatrick CJ
    Acta Haematol; 2009; 122(1):36-8. PubMed ID: 19713696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel cytogenetic abnormality in primary myelofibrosis.
    Bae SY; Kim JS; Lee KN; Lee CK; Kim YK; Yoon SY; Lim CS; Cho YJ; Choi CW; Kim WY
    Cancer Genet Cytogenet; 2009 Oct; 194(1):65-6. PubMed ID: 19737657
    [No Abstract]   [Full Text] [Related]  

  • 23. New insights into the pathogenesis and drug treatment of myelofibrosis.
    Tefferi A
    Curr Opin Hematol; 2006 Mar; 13(2):87-92. PubMed ID: 16456374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A sensitive and reliable semi-quantitative real-time PCR assay to detect JAK2 V617F in blood.
    Poodt J; Fijnheer R; Walsh IB; Hermans MH
    Hematol Oncol; 2006 Dec; 24(4):227-33. PubMed ID: 17006961
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
    Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytogenetic and clinical studies of a male infant with disorder of sexual development: case report.
    Balkan M; Duran H; Onen A; Oral D; Isi H; Fidanboy M; Alp MN; Budak T
    Fertil Steril; 2008 Nov; 90(5):2003.e13-6. PubMed ID: 18691707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of breakpoint cluster regions at 1p36.3 and 3q21 in hematologic malignancies with t(1;3)(p36;q21).
    Shimizu S; Suzukawa K; Kodera T; Nagasawa T; Abe T; Taniwaki M; Yagasaki F; Tanaka H; Fujisawa S; Johansson B; Ahlgren T; Yokota J; Morishita K
    Genes Chromosomes Cancer; 2000 Mar; 27(3):229-38. PubMed ID: 10679911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aberrant collagenase expression in chronic idiopathic myelofibrosis is related to the stage of disease but not to the JAK2 mutation status.
    Bock O; Neuse J; Hussein K; Brakensiek K; Buesche G; Buhr T; Wiese B; Kreipe H
    Am J Pathol; 2006 Aug; 169(2):471-81. PubMed ID: 16877349
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular cytogenetic characterization of variant Philadelphia translocations in chronic myeloid leukemia: genesis and deletion of derivative chromosome 9.
    Bennour A; Sennana H; Laatiri MA; Elloumi M; Khelif A; Saad A
    Cancer Genet Cytogenet; 2009 Oct; 194(1):30-7. PubMed ID: 19737651
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Translocation t(3;12)(q26;q21) in JAK2(V617F) Point Mutation Negative Chronic Idiopathic Myelofibrosis: A Case Report.
    Mešanović S; Šahović H; Perić M
    Balkan J Med Genet; 2014 Jun; 17(1):63-8. PubMed ID: 25741217
    [TBL] [Abstract][Full Text] [Related]  

  • 31. JAK2 mutation in a patient with CLL with coexistent myeloproliferative neoplasm (MPN).
    Kodali S; Chen C; Rathnasabapathy C; Wang JC
    Leuk Res; 2009 Dec; 33(12):e236-9. PubMed ID: 19625083
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [The application of fluorescence in situ hybridization in detecting chronic myeloid leukemia].
    Qiu HR; Miao KR; Wang R; Qiao C; Zhang JF; Zhang SJ; Qian SX; Xu W; Li JY
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2009 Apr; 26(2):207-10. PubMed ID: 19350518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recurrent chromosomal aberration at 12q15 in chronic idiopathic myelofibrosis with or without JAK2(V617F) mutation.
    Ohyashiki K; Tauchi T; Kuroda M; Kodama A; Ohyashiki JH
    Leukemia; 2007 Jul; 21(7):1578-80. PubMed ID: 17443223
    [No Abstract]   [Full Text] [Related]  

  • 34. Fluorescence in situ hybridization dissection of a chronic myeloid leukemia case bearing the apparently balanced translocations (9;22)(q34;q11.2) and (11;11)(p15;q13).
    Malvestiti F; Colombo D; Perego D; Rodeschini O; Finelli P; Larizza L; Giardino D
    Cancer Genet Cytogenet; 2009 Jan; 188(1):42-7. PubMed ID: 19061779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular cytogenetic detection of 9q34 breakpoints associated with nail patella syndrome.
    Silahtaroglu A; Hol FA; Jensen PK; Erdel M; Duba HC; Geurds MP; Knoers NV; Mariman EC; Tümer Z; Utermann G; Wirth J; Bugge M; Tommerup N
    Eur J Hum Genet; 1999 Jan; 7(1):68-76. PubMed ID: 10094193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fluorescent in situ hybridization (FISH) in bone marrow and peripheral blood of leukemia patients: implications for occupational surveillance.
    McDevitt MA; Condon M; Stamberg J; Karp JE; McDiarmid M
    Mutat Res; 2007 Apr; 629(1):24-31. PubMed ID: 17276720
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hematopoietic neoplasms with 9p24/JAK2 rearrangement: a multicenter study.
    Tang G; Sydney Sir Philip JK; Weinberg O; Tam W; Sadigh S; Lake JI; Margolskee EM; Rogers HJ; Miranda RN; Bueso-Ramos C C; Hsi ED; Orazi A; Hasserjian RP; Arber DA; Bagg A; Wang SA
    Mod Pathol; 2019 Apr; 32(4):490-498. PubMed ID: 30401948
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytogenetics of agnogenic myeloid metaplasia: a study of 61 patients.
    Djordjevic V; Dencic-Fekete M; Jovanovic J; Bizic S; Jankovic G; Bogdanovic A; Cemerikic-Martinovic V; Gotic M
    Cancer Genet Cytogenet; 2007 Feb; 173(1):57-62. PubMed ID: 17284371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rearrangements involving 12q in myeloproliferative disorders: possible role of HMGA2 and SOCS2 genes.
    Etienne A; Carbuccia N; Adélaïde J; Bekhouche I; Rémy V; Sohn C; Sainty D; Gastaut JA; Olschwang S; Birnbaum D; Mozziconacci MJ; Chaffanet M
    Cancer Genet Cytogenet; 2007 Jul; 176(1):80-8. PubMed ID: 17574970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis.
    Andrieux J; Roche-Lestienne C; Geffroy S; Desterke C; Grardel N; Plantier I; Selleslag D; Demory JL; Laï JL; Leleu X; Le Bousse-Kerdiles C; Vandenberghe P
    Cancer Genet Cytogenet; 2007 Oct; 178(1):11-6. PubMed ID: 17889703
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.